Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxcarbazepine as a neuroprotective agent in MS: phase 2a trial
2013-002419-87Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in multiple sclerosis (MS) comparing Oxcarbazepine with Placebo (2 arms). Primary endpoints: Primary neuroprotective effect and Early neuroprotective effect at 6 months. Started Feb 2014; status: completed.
02
Drugs
oxcarbazepine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-002419-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002419-87.